Literature DB >> 20236205

Psoriasis: an epidemiological evaluation of disease burden in 590 patients.

N Meyer1, C Paul, D Feneron, I Bardoulat, C Thiriet, C Camara, D Sid-Mohand, C Le Pen, J P Ortonne.   

Abstract

BACKGROUND: There are limited data available on the economical burden of psoriasis and its impact on everyday life.
OBJECTIVE: The aim of this study was to evaluate the impact of psoriasis on personal and professional life, and to evaluate the cost of psoriasis for the patient.
METHODS: We performed a cross-sectional study in psoriasis patients. All patients aged >or=18 years with a diagnosis of plaque-psoriasis confirmed by a physician were included. A self-administered questionnaire evaluating everyday life was constructed with members of the French association of psoriasis patients. In addition, the Dermatology Life Quality Index (DLQI), Working Productivity and Activity Impairment and individual costs were assessed.
RESULTS: A total of 590 patients completed the study. Mean age of the responders was 56 years. The mean DLQI score was 8.5 for patients with severe psoriasis vs. 6.4 for mild psoriasis. Global loss of productivity was 10.7% without significant difference according to the disease severity. Daily activities alteration was most important in patients with severe psoriasis. In this study, 36.8% of patients with severe psoriasis reported a negative impact on their professional life vs. 19.6% for patients with mild psoriasis (P = 0.002). Time devoted to phototherapy was on average 33 h/year/patient and the application of emollients took 25 h/year/patient; 47.3% of patients had a feeling to clean the house more often, in correlation with the severity of the disease. Mean out-of-pocket expenses for the disease was estimated to be 543 euro/year/patient. High impact of psoriasis on quality of life (DLQI >10), age <40 years and joint involvement were significantly associated with an increased risk of loss of work productivity.
CONCLUSION: Psoriasis, particularly severe psoriasis, is a true burden for patients and impacts significantly everyday life and patient's economical resources.

Entities:  

Mesh:

Year:  2010        PMID: 20236205     DOI: 10.1111/j.1468-3083.2010.03600.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  21 in total

1.  Dyadic adjustment, family coping, body image, quality of life and psychological morbidity in patients with psoriasis and their partners.

Authors:  M Graça Pereira; Laura Brito; Tom Smith
Journal:  Int J Behav Med       Date:  2012-09

2.  Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire.

Authors:  Esteban Dauden; Enrique Herrera; Lluis Puig; José Luis Sánchez-Carazo; Jaime Toribio; Ma Teresa Caloto; Gonzalo Nocea; Montse Roset; Nuria Lara
Journal:  Health Qual Life Outcomes       Date:  2012-05-24       Impact factor: 3.186

3.  Family burden in inherited ichthyosis: creation of a specific questionnaire.

Authors:  Hélène Dufresne; Smail Hadj-Rabia; Cécile Méni; Vincent Sibaud; Christine Bodemer; Charles Taïeb
Journal:  Orphanet J Rare Dis       Date:  2013-02-15       Impact factor: 4.123

4.  Influence of Psoriasis on Household Chores and Time Spent on Skin Care at Home: A Questionnaire Study.

Authors:  Mauri Leino; Anssi Mustonen; Kalle Mattila; Leena Koulu; Risto Tuominen
Journal:  Dermatol Ther (Heidelb)       Date:  2015-05-05

Review 5.  Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.

Authors:  Philip J Mease; April W Armstrong
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

6.  The costs of psoriasis medications.

Authors:  Anssi Mustonen; Kalle Mattila; Mauri Leino; Leena Koulu; Risto Tuominen
Journal:  Dermatol Ther (Heidelb)       Date:  2013-12-13

7.  Psoriasis causes significant economic burden to patients.

Authors:  A Mustonen; K Mattila; M Leino; L Koulu; R Tuominen
Journal:  Dermatol Ther (Heidelb)       Date:  2014-05-28

8.  How much of the productivity losses among psoriasis patients are due to psoriasis.

Authors:  Anssi Mustonen; Kalle Mattila; Mauri Leino; Leena Koulu; Risto Tuominen
Journal:  BMC Health Serv Res       Date:  2015-03-04       Impact factor: 2.655

9.  Effect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis.

Authors:  Pratik Gahalaut; Nitin Mishra; Puneet S Soodan; Madhur K Rastogi
Journal:  Dermatol Res Pract       Date:  2014-09-04

10.  Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.

Authors:  Vibeke Strand; David Fiorentino; ChiaChi Hu; Robert M Day; Randall M Stevens; Kim A Papp
Journal:  Health Qual Life Outcomes       Date:  2013-05-10       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.